Back
Open Access

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

Session: Poster session 7 - Heart failure / Left ventricular dysfunction
Topic: Pharmacologic therapy
Speaker: Doctor T. Mondritzki (Wuppertal, DE)
Event: ESC CONGRESS 2016

Congress Session

0

About the speaker

Doctor Thomas Mondritzki

Bayer AG, Wuppertal (Germany)
0 follower

49 more presentations in this session

Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial

Speaker: Associate Professor H. Duengen (Berlin, DE)

Access
Abstract
0
Thumbnail

The use of Guideline recommended betablocker therapy in primary prevention ICD patients. Insight from Danish nationwide registries

Speaker: Doctor A. Huth Ruwald (Roskilde, DK)

Access
Abstract
Slides
0
Thumbnail

The effect of angiotensin II type 2 receptor agonist treatment on doxorubicin induced heart failure

Speaker: Associate Professor N. Ermis (Malatya, TR)

Access
Abstract
Slides
0
Thumbnail

Triiodo-L-thyronine promotes the therapeutic efficacy for myocardial infarction of bone marrow mesenchymal stem cells

Speaker: Professor S. Nie (Beijing, CN)

Access
Abstract
Slides
0
Thumbnail

Vasodilator nicorandil in acute heart failure patients with aortic stenosis

Speaker: Doctor K. Harada (Tokushima, JP)

Access
Abstract
0
Thumbnail

Access the full session

Poster session 7 - Heart failure / Left ventricular dysfunction

Speakers: Doctor T. Mondritzki, Associate Professor H. Duengen, Doctor A. Huth Ruwald, Associate Professor N. Ermis, Professor S. Nie...
Access
0
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

Congress
logo Image

This platform is supported by

logo Novo Nordisk